Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M105,137Revenue (TTM) $M26,218Net Margin (%)24.1Altman Z-Score2.1
Enterprise Value $M135,840EPS (TTM) $3.9Operating Margin %36.3Piotroski F-Score6
P/E(ttm)17.1Beneish M-Score-2.4Pre-tax Margin (%)31.3Higher ROA y-yN
Price/Book21.110-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %9.5Current Ratio1.8Lower Leverage y-yY
Price/Free Cash Flow16.3y-y EBITDA Growth Rate %22.0ROA % (ttm)9.9Higher Current Ratio y-yY
Dividend Yield %3.7PEG1.8ROE % (ttm)119Less Shares Outstanding y-yY
Payout Ratio %61.0Shares Outstanding M1,592ROIC % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ABBV is held by these investors:



ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GONZALEZ RICHARD AChairman of the Board and CEO 2017-05-19Sell71,235$65.490.87view
CHASE WILLIAM JEVP, CFO 2017-05-18Sell38,300$65.351.09view
ALBAN CARLOSEVP, Commercial Operations 2017-05-04Sell43,000$67-1.4view
Michael Robert A.VP, Controller 2017-03-10Sell5,132$65.291.18view
Schumacher Laura JExecutive Vice President 2017-03-10Sell40,000$65.261.23view
RICHMOND TIMOTHY J.SVP, Human Resources 2017-03-10Sell22,451$65.291.18view
GONZALEZ RICHARD AChairman of the Board and CEO 2017-03-08Sell72,016$64.252.82view
HURWICH THOMAS A.VP, Controller 2017-02-28Sell2,311$61.896.74view
CHASE WILLIAM JEVP, CFO 2016-12-02Sell6,600$59.1911.61view
HURWICH THOMAS A.VP, Controller 2016-11-16Sell3,100$626.55view

Press Releases about ABBV :

Quarterly/Annual Reports about ABBV:

News about ABBV:

Articles On GuruFocus.com
AbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference May 24 2017 
What Drug Approval Means for Neurocrine Biosciences May 19 2017 
AbbVie's Humira Loses Patent in Coherus’ Petitions May 18 2017 
IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical E May 14 2017 
AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1- May 09 2017 
AbbVie to Present at the UBS Global Healthcare Conference May 05 2017 
AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking St May 04 2017 
AbbVie Reports Humira Sales Growth in 1st Quarter Apr 28 2017 
AbbVie’s Humira Revenue Up 15% Despite Patent Cliff Fears Apr 28 2017 
Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthr Apr 25 2017 

More From Other Websites
The 2 Best Dividend Stocks in Marijuana May 27 2017
Top Presentations to Look for at ASCO May 27 2017
Blog Coverage: Pfizer Cautions Shareholders Against Accepting TRC Capital Corporation's Mini-Tender... May 26 2017
Major Pharma Short Interest Surges May 25 2017
Biogen's Fampyra Conditional Approval Converted to Standard May 25 2017
Neupogen and Enbrel Could See Falling Revenues in 2017 May 24 2017
AbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference May 24 2017
AbbVie Expects Rivals To Chip Away At Its Biggest Drug Franchise May 23 2017
Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis May 23 2017
The 3 Best Dividend Stocks in Arthritis Medication May 22 2017
[$$] AmerisourceBergen and AbbVie Top Barron's 500 May 20 2017
The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco May 19 2017
AbbVie to Present at the Jefferies 2017 Global Healthcare Conference May 19 2017
For millions of Chinese with rare diseases, some relief in sight May 18 2017
AbbVie's Humira Loses Patent in Coherus' Petitions May 18 2017
Top 4 Marijuana Stocks to Watch for 2017 May 18 2017
New Stock Research Reports for Boeing, AbbVie and UnitedHealth May 18 2017
[$$] AbbVie: It's the Pipeline, Not the Coherus Ruling May 18 2017
AbbVie Down on Humira Patent Loss: Is More Damage in Store? May 18 2017
AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : May 18, 2017 May 18 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)